Radiotherapy & Oncology
Volume 92, Issue 1 , Pages 1-3 , July 2009

Chemoradiotherapy of head and neck cancer – Can the bumble bee fly?

  • Jens Overgaard

      Affiliations

    • Corresponding Author InformationAddress: Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, Bld. 5, DK-8000 Aarhus C, Aarhus, Denmark.

Received 4 June 2009 ,Accepted 4 June 2009.

References 

  1. Tannock IF. Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol. 1989;16:83–101
  2. Steel GG, editor. Basic clinical radiobiology. London: Edward Arnold; 1993.
  3. Pignon JP, Maître AL, Maillard E, Bourhis J. On behalf of the MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009:92;4–14.
  4. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–854
  5. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47–56
  6. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949–955
  7. Henk JM. Concomitant chemoradiation for head and neck cancer: saving lives or grays?. Clin Oncol (R Coll Radiol). 2001;13:333–335
  8. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26:3582–3589
  9. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25:4096–4103
  10. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–2447
  11. Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98
  12. Corvò R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol. 2007;85:156–170
  13. Thomas GM. Improved treatment for cervical cancer–concurrent chemotherapy and radiotherapy. N Engl J Med. 1999;340:1198–1200
  14. Peters LJ, Ang KK, Thames HD. Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol. 1988;27:185–194
  15. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18–24
  16. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066–4074
  17. Grau C, Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol. 1988;13:301–309
  18. Grau C, Agarwal JP, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, et al. Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol. 2003;67:17–26
  19. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933–940
  20. Hansen O, Overgaard J, Hansen HS, Overgaard M, Höyer M, Jörgensen KE, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol. 1997;43:47–51
  21. Eriksen JG, Buffa FM, Alsner J, Steiniche T, Bentzen SM, Overgaard J. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother Oncol. 2004;72:275–282
  22. Bastholt L, Specht L, Jensen K, Brun E, Loft A, Petersen J, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2007;85:24–28
  23. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  24. Mydin AR, Armstrong JG. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol. 2007;85:171
  25. Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in headand neck cancer: results of a survey in EORTC institutes. Radiother Oncol. 2009;90:166–171
  26. Pryor DI, Porceddu SV, Burmeister BH, Guminski A, Thomson DB, Shepherdson K, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol. 2009;90:172–176
  27. Eriksen JG, Overgaard M. Late onset of skin toxicity induced by EGFr-inhibitors. Adiother Oncol. 2009;90:280–281
  28. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1992–1998
  29. Bernier J. Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol. 2009;19:3–10

PII: S0167-8140(09)00274-6

doi: 10.1016/j.radonc.2009.06.001

Radiotherapy & Oncology
Volume 92, Issue 1 , Pages 1-3 , July 2009

Article Tools